ArriVent BioPharmavsEli Lilly and Company

AVBP and LLY stock compared: price, dividend, valuation and results, from SEC filings.

AVBP

ArriVent BioPharma, Inc.

$10.90

Value $564M

-7.53%
AVBP's page

LLY

Eli Lilly and Company

$1,382.75

Value $1.30T

-1.13%
LLY's page

ArriVent BioPharma (AVBP) has a market value of $564M and Eli Lilly and Company (LLY) $1.30T. Over the last year, with dividends, AVBP moved -48.3% and LLY +38.9%. Dividend yield: AVBP none, LLY 0.46%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AVBP$564M

    LLY$1.30T

    LLY is 2,314 times AVBP

  • Revenue, 12 months

    AVBP–

    LLY$86.5B

  • Net income, 12 months

    AVBP-$169M

    LLY$27.6B

  • Operating margin

    AVBP–

    LLY–

  • ROIC

    AVBP-45.7%

    LLY35.5%

    81.1 points apart

  • P/E

    AVBP–

    LLY47.3

  • Dividend yield

    AVBP0.0%

    LLY0.5%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AVBP-48.3%

LLY+38.9%

50100150DecFebAprJunAugOct
Returns by period
PeriodAVBPWith dividendsLLYWith dividends
1 year since November 14, 2025-48.3%Price -48.3%+38.9%Price +38.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AVBPArriVent BioPharmaLLYEli Lilly and Company

Valuation

AVBPLLY
Valuation
Price$10.90$1,382.75
Market value$564M$1.30T
Enterprise value (EV)$171M$1.35T
P/E–47.3
P/E, 5-year median–49.9
P/B1.432.4
EV/EBIT–38.8
Free cash flow yield–1.5%

Results and growth

AVBPLLY
Results and growth
Revenue, 12 months–$86.5B
Net income, 12 months-$169M$27.6B
Free cash flow, 12 months–$19.7B
Earnings per share, 12 months-$3.60$30.81
Revenue growth, year on year–44.7%
Revenue growth a year, past–+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

AVBPLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin––
Net margin–31.9%
ROIC-45.7%35.5%
ROE-49.8%88.6%

Balance sheet

AVBPLLY
Balance sheet
Cash$393M$4.9B
Total debt$256.0K$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

AVBPLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AVBP or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, ArriVent BioPharma or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.30T) is about 2,313.7 times ArriVent BioPharma ($564M), at today's prices.

How did AVBP and LLY stock do over the last 1 years?

Since November 14, 2025, AVBP's price moved -48.3% and LLY's +38.1%. With dividends: AVBP -48.3% (-48.3% a year), LLY +38.9% (+38.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, AVBP or LLY?

The dividend yield at today's price is none for ArriVent BioPharma and 0.46% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which is the better investment, ArriVent BioPharma or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.